Sasson AN, Ingram RJM, Zhang Z, Taylor LM, Ananthakrishnan AN, Kaplan GG, et al
Other weight loss medications in trials Cagrilintides potential value isnt about having the highest weight-loss percentage in the field
4 Bioactive ginsenosides in metabolic and inflammatory liver disorders Non-alcoholic fatty liver disease (NAFLD) can progress to a more severe stage called NASH, which involves inflammation and liver scarring
Endogenous Pigmentation Oral pigmented lesions caused by endogenous pigments, particularly those derived from blood, represent a significant clinical concern
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity